Our award-winning investments in the US
We are growing globally and continuously investing to strengthen and expand our position in the biopharmaceutical market. Our long-term goal is to increase capacity and attract more pharmaceutical customers by establishing ourselves as a strong and reliable partner. To this end, we recently launched a major project at our new Des Plaines site, investing over $285 million to build a state-of-the-art clinical facility.
The German American Chamber of Commerce welcomed this move by designating the project and the resulting facility as the "Investment of the Year 2026." This distinction for our key project underlines the fact that our expertise and reliability are recognized and valued in the strategically important US market. Each year, the “Investment of the Year” award recognizes German companies that make significant investments in the United States. This award further reinforces our position in the German export industry and the global pharmaceutical landscape. We are very proud to have received this prestigious distinction, which was announced at the 2026 German American Executive Summit in New Orleans.
We are grateful for this award, which recognizes the growing importance of Vetter's presence in the biopharmaceutical market in the United States. Our new, state-of-the-art facility further underscores our commitment to supporting customers in their journey through the complex clinical development of promising new drugs. By investing in additional capacity, we are responding to the growing demand for reliable, high-quality manufacturing services.
Susanne Lemaine, Vice President VDS Chicago
The new location in Des Plaines
The new 14,900-square-meter facility will greatly enhance our clinical development capabilities. This location will also have a significant impact on the business community by creating up to 200 new jobs in the long term. What’s more, the facility is slated for future expansion.
The award is not the only reason to celebrate: The Des Plaines project is right on schedule! Since the groundbreaking ceremony in June 2025, construction has proceeded according to plan. Our goal is to have this key component of our global strategy up and running by the end of 2029. Winning the "Investment of the Year 2026" award has only added to our anticipation.
